| Literature DB >> 32509870 |
Dehui Lai1,2,3, Yongzhong He1,2, Xun Li1,2, Meiling Chen1,2, Xingrong Zeng3.
Abstract
OBJECTIVE: Comparison of outcomes between RIRS with vacuum-assisted ureteral access sheath (V-UAS) and MPCNL in the treatment of renal stone.Entities:
Mesh:
Year: 2020 PMID: 32509870 PMCID: PMC7245689 DOI: 10.1155/2020/8052013
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1(a) Sucking out the tiny fragments and dust during lithotripsy by V-UAS: (A) inserting a flexible endoscope into the sheath through the aperture of rubber cap to gain a closed system, (B) the oblique drainage tube was connected to a negative pressure aspirator, and (C) a stone collection bottle is connecting the UAS and the negative pressure suction. (b) Structure of V-UAS: (A) straight introduced tube with a red marker, (B) rubber cap, and (C) oblique drainage tube. (c) Structure of oblique drainage tube in V-UAS: (A) a longitudinal slit on this oblique drainage tube that is a pressure-regulating vent.
Demographic data of patients.
| Variable | Group A (RIRS) | Group B (MPCNL) |
|
|---|---|---|---|
| 28 patients | 56 patients | ||
| Age (year), mean (SD), range | 45.2 (10.4), 21-65 | 49.6 (12.2), 23-72 | 0.296 |
| Gender (males/females) | 16/12 | 26/30 | 0.355 |
| BMI (kg/m2), mean (SD), range | 24.98 (3.51), 19-32 | 25.32 (4.12), 20-33 | 0.104 |
| Stone-affected side (left/right) | 13/15 | 30/26 | 0.537 |
| Grade of hydronephrosis (no.) | 0.061 | ||
| None | 16 | 20 | |
| Mild | 12 | 36 | |
| Charlson comorbidity index | 0.864 | ||
| 0 (%) | 13 | 24 | |
| 1 (%) | 10 | 18 | |
| 2 (%) | 3 | 10 | |
| 3 (%) | 2 | 4 | |
| Renal stone location, no. (%) | 0.562 | ||
| Renal pelvic+upper pole | 7 | 17 | |
| Renal pelvic+middle pole | 4 | 12 | |
| Renal pelvic+lower pole | 6 | 11 | |
| Renal pelvic+middle pole+lower pole | 5 | 11 | |
| Renal pelvic+upper pole+middle pole | 6 | 5 | |
| Largest stone size (mm), mean (SD), range | 35.3 (6.3), 25-39 | 38.2 (5.4), 28-40 | 0.074 |
| Renal stone burden (mm2), mean (SD), range | 676.1 (42.2), 391.2-803.4 | 729 (83.7), 412.3-843.2 | 0.089 |
| Stone density (HU), mean (SD), range | 894.3 (232.3), 650-1103 | 845.2 (240.2), 600-1206 | 0.43 |
| Positive urine culture, no. (%) | 8 (28.6%) | 21 (37.5%) | 0.417 |
Perioperative and postoperative data of patients.
| Variable | Group A (RIRS) | Group B (MPCNL) |
|
|---|---|---|---|
| 28 patients | 56 patients | ||
| Fluoroscopy time (min), mean (SD), range | 1.6 (0.5), 0.8-3.5 | 4.4 (2.1), 2-10 | <0.001 |
| Operative time (min), mean (SD), range | 72.4 (21.3), 42-106 | 67.4 (25), 44-114 | 0.042 |
| Hospitalization stay (days), mean (SD), range | 4.3 (2.9), 2-10 | 6.1 (3.2), 2-20 | <0.001 |
| Hemoglobin drop (g/dL), mean (SD) | 0.5 (0.21), 0.1-0.7 | 1.9 (1.3), 0.5-4 | <0.001 |
| Complication (modified Clavien classification), no. (%) | 6 (21.4%) | 13 (23.2%) | 0.854 |
| Grade I | 3 | 8 | |
| Fever | 2 | 5 | |
| Emesis | 1 | 3 | |
| Grade II | 1 | 4 | |
| Infection | 1 | 2 | |
| Blood transfusion | 0 | 2 | |
| Grade IIIa | 1 | 1 | |
| Perforation | 1 | 1 | |
| Grade IIIb | 1 | 0 | |
| Steinstrasse | 1 | 0 | |
| Pain visual analogue score (1–10), mean (SD), range | |||
| At 6 h | 3.3 (1.3), 2-5 | 5.4 (1.1), 4-8 | <0.001 |
| At 24 h | 2.0 (0.9), 2-5 | 4.2 (1.2), 3-8 | <0.001 |
| At 48 h | 1.1 (0.3), 1-3 | 2.8 (1.4), 1-5 | <0.001 |
| Postoperative analgesics (diclofenac sodium), no. (%) | 4 (14.3%) | 23 (41.1%) | 0.013 |
| Initial stone-free rate, no. (%) | 14 (50%) | 41 (73.2%) | 0.035 |
| Final stone-free rate, no. (%) | 25 (89.3%) | 52 (92.9%) | 0.681 |
| Residual size (mm), mean (SD), range | 21.1 (1.3), 15-22 | 25.1 (2.4), 13-23 | 0.06 |
| Auxiliary procedures, no. (%) | 12 (42.9%) | 14 (25%) | 0.095 |
| Second-stage RIRS | 12 | ||
| Second-look PCNL+RIRS | 14 | ||
| Procedure per patient, mean (SD), range | 1.43 (0.48), 1-2 | 1.25 (0.44), 1-2 | 0.255 |
| Stone composition, no. (%) | 0.8 | ||
| Calcium oxalate | 11 (39.3%) | 28 (50%) | |
| Calcium oxalate and phosphate | 6 (21.4%) | 11 (19.6%) | |
| Uric acid | 4 (14.3%) | 7 (12.5%) | |
| Struvite | 7 (25%) | 10 (17.9%) |